Phase I-II Study of Avastin [bevacizumab] + Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC [non-small cell lung cancer].
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Jan 2012 Planned end date (May 2007) added as reported by ClinicalTrials.gov.
- 20 Jan 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Jan 2007 New trial record.